Favipiravir and/or Nitazoxanide: a Randomized, Double-blind, Placebo-controlled Trial of Early Antiviral Therapy in COVID-19 (FANTAZE)

Smith et al., NCT04918927, FANTAZE, NCT04918927, Mar 2023
120 patient favipiravir early treatment RCT with results not reported over 3 years after completion.
The protocol has been published1.
Potential risks of favipiravir include kidney injury2-4, liver injury3-6, cardiovascular events6,7, pulmonary toxicity7,8, and mutagenicity, carcinogenicity, teratogenicity, embryotoxicity, and the creation of dangerous variants9-15.
2 favipiravir RCTs have results missing long after expected16,17
The trials report total actual enrollment of 1,128 patients.
Study covers favipiravir and nitazoxanide.
Smith et al., 21 Mar 2023, Double Blind Randomized Controlled Trial, Mexico, trial NCT04918927 (history) (FANTAZE). Contact: jorgeep@unam.mx.